Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426324 | 0.93 | CTSL (0.33) | NPC1LMNARAB9ASMN1; SMN2ENPP2 | |
| SCHEMBL6427278 | 0.88 | MAOA (0.32) | ENPP2CTSLMMP1PTGS2 | |
| SCHEMBL6430160 | 0.87 | ENPP2 (0.31) | NPC1LMNARAB9ASMN1; SMN2ENPP2 | |
| SCHEMBL6428560 | 0.83 | ENPP2 (0.32) | ENPP2CTSLMMP1PTGS2 | |
| SCHEMBL6427406 | 0.83 | ENPP2 (0.33) | ENPP2CTSLMMP1PTGS2 | |
| SCHEMBL6428655 | 0.82 | TUBB4A (0.32) | ENPP2CTSLPTGS2 | |
| SCHEMBL6425946 | 0.82 | ENPP2 (0.33) | ENPP2CTSLMMP1PTGS2 | |
| SCHEMBL6426059 | 0.80 | KDM4C (0.32) | ENPP2 | |
| SCHEMBL6427836 | 0.80 | ENPP2 (0.32) | ENPP2CTSLMMP1PTGS2 | |
| SCHEMBL6426373 | 0.80 | TUBB4A (0.32) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | NPC1 3703/4885LMNA 3498/4885RAB9A 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.